FORM
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
For
the quarterly period ended
Commission
file number
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) | |
| Address of principal executive offices) | (Zip Code) | |
Registrant’s
telephone number, including area code: (
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☒ NO ☐.
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for shorter period that the registrant was required
to submit such files
| Page 1 |
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See definition of accelerated filer, large accelerated filer, smaller reporting company and emerging growth
company in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name
of each exchange on which registered | ||
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the close of the latest practicable date.
| Class | Outstanding at February 3, 2025 | |||
| Common Stock, par value $.0001 | ||||
| Class B Common Stock, par value $.0001 | ||||
| Class C Common Stock, par value $.0001 | ||||
| Class A Preferred Stock, par value $.0001 | ||||
| Page 2 |
FONAR CORPORATION AND SUBSIDIARIES
INDEX
| Page 3 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
ASSETS
| December
31, 2024 (Unaudited) | June
30, 2024 (Note 1) | |||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Short-term investments | ||||||||
| Accounts
receivable – net of allowance for credit losses of $ | ||||||||
| Accounts receivable _ related party | ||||||||
| Medical receivable – net | ||||||||
| Management
and other fees receivable – net of allowance for credit losses of $ | ||||||||
| Management
and other fees receivable – related medical practices – net of allowance for credit losses of $ | ||||||||
| Inventories | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total Current Assets | ||||||||
| Accounts receivable – long term | ||||||||
| Deferred income tax asset | ||||||||
| Property and equipment – net | ||||||||
| Note receivable – related party | ||||||||
| Right-of-use-asset – operating leases | ||||||||
| Right-of-use-asset – financing lease | ||||||||
| Goodwill | ||||||||
| Other intangible assets – net | ||||||||
| Other assets | ||||||||
| Total Assets | $ | $ | ||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| Page 4 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
(Amounts and shares in thousands, except per share amounts)
LIABILITIES AND EQUITY
| December
31, 2024 (Unaudited) | June
30, 2024 (Note 1) | |||||||
| Current Liabilities: | ||||||||
| Current portion of long-term debt | $ | $ | ||||||
| Accounts payable | ||||||||
| Other current liabilities | ||||||||
| Unearned revenue on service contracts | ||||||||
| Unearned revenue on service contracts – related party | ||||||||
| Operating lease liabilities _ current portion | ||||||||
| Financing lease liability _ current portion | ||||||||
| Customer deposits | ||||||||
| Total Current Liabilities | ||||||||
| Long-Term Liabilities: | ||||||||
| Unearned revenue on service contracts | ||||||||
| Deferred income tax liability | ||||||||
| Due to related party medical practices | ||||||||
| Operating lease liabilities – net of current portion | ||||||||
| Financing lease liability – net of current portion | ||||||||
| Long-term debt, less current portion | ||||||||
| Other liabilities | ||||||||
| Total Long-Term Liabilities | ||||||||
| Total Liabilities | ||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| Page 5 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
(Amounts and shares in thousands, except per share amounts)
LIABILITIES AND EQUITY (Continued)
| EQUITY: | December
31, 2024 (Unaudited) | June
30, 2024 (Note 1) | ||||||
Class A non-voting preferred stock $par value; shares authorized at December 31, 2024 and June 30, 2024, issued and outstanding at December 31, 2024 and June 30, 2024 | $ | $ | ||||||
| Preferred stock $par value; shares authorized at December 31, 2024 and June 30, 2024, issued and outstanding – | ||||||||
| Common Stock $par value; shares authorized at December 31, 2024 and June 30, 2024, and issued at December 31, 2024 and June 30, 2024, respectively, and outstanding at December 31, 2024 and June 30, 2024, respectively | ||||||||
| Class B Common Stock (10 votes per share) $par value; shares authorized at December 31, 2024 and June 30, 2024, issued and outstanding at December 31, 2024 and June 30, 2024 | ||||||||
| Class C Common Stock (25 votes per share) $par value; shares authorized at December 31, 2024 and June 30, 2024, issued and outstanding at December 31, 2024 and June 30, 2024 | ||||||||
| Paid-in capital in excess of par value | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Treasury stock, at cost – shares of common stock at December 31, 2024 and shares of common stock at June 30, 2024 | ( | ) | ( | ) | ||||
| Total FONAR Corporation’s Stockholders’ Equity | ||||||||
| Noncontrolling interests | ( | ) | ( | ) | ||||
| Total Equity | ||||||||
| Total Liabilities and Equity | $ | $ | ||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| Page 6 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts and shares in thousands, except per share amounts)
| FOR
THE THREE MONTHS ENDED DECEMBER 31, (Unaudited) | ||||||||
| REVENUES | 2024 | 2023 | ||||||
| Patient fee revenue – net of contractual allowances and discounts | $ | $ | ||||||
| Product sales | ||||||||
| Service and repair fees | ||||||||
| Service and repair fees _ related parties | ||||||||
| Management and other fees | ||||||||
| Management and other fees _ related medical practices | ||||||||
| Total Revenues – Net | ||||||||
| COSTS AND EXPENSES | ||||||||
| Costs related to patient fee revenue | ||||||||
| Costs related to product sales | ||||||||
| Costs related to service and repair fees | ||||||||
| Costs related to service and repair fees _ related parties | ||||||||
| Costs related to management and other fees | ||||||||
| Costs related to management and other fees – related medical practices | ||||||||
| Research and development | ||||||||
| Selling, general and administrative expenses | ||||||||
| Total Costs and Expenses | ||||||||
| INCOME FROM OPERATIONS | ||||||||
| Other income and (expenses) | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Investment income – related party | ||||||||
| Investment income | ||||||||
| Other income – related party | ||||||||
| Other income | ||||||||
| Income Before Provision for Income Taxes and Noncontrolling Interests | ||||||||
| Provision for income taxes | ( | ) | ( | ) | ||||
| Consolidated Net Income | ||||||||
| Net Income - Noncontrolling Interests | ( | ) | ( | ) | ||||
| Net Income – Attributable to FONAR | $ | $ | ||||||
| Net Income Available to Common Stockholders | $ | $ | ||||||
| Net Income Available to Class A Non-Voting Preferred Stockholders | $ | $ | ||||||
| Net Income Available to Class C Common Stockholders | $ | $ | ||||||
| Basic Net Income Per Common Share Available to Common Stockholders | $ | $ | ||||||
| Diluted Net Income Per Common Share Available to Common Stockholders | $ | $ | ||||||
| Basic and Diluted Income Per Share – Class C Common | $ | $ | ||||||
| Weighted Average Basic Shares Outstanding – Common Stockholders | ||||||||
| Weighted Average Diluted Shares Outstanding _ Common Stockholders | ||||||||
| Weighted Average Basic and Diluted Shares Outstanding _ Class C Common | ||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| Page 7 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts and shares in thousands, except per share amounts)
| FOR
THE SIX MONTHS ENDED DECEMBER 31, (Unaudited) | ||||||||
| REVENUES | 2024 | 2023 | ||||||
| Patient fee revenue – net of contractual allowances and discounts | $ | $ | ||||||
| Product sales | ||||||||
| Service and repair fees | ||||||||
| Service and repair fees _ related parties | ||||||||
| Management and other fees | ||||||||
| Management and other fees _ related medical practices | ||||||||
| Total Revenues – Net | ||||||||
| COSTS AND EXPENSES | ||||||||
| Costs related to patient fee revenue | ||||||||
| Costs related to product sales | ||||||||
| Costs related to service and repair fees | ||||||||
| Costs related to service and repair fees _ related parties | ||||||||
| Costs related to management and other fees | ||||||||
| Costs related to management and other fees – related medical practices | ||||||||
| Research and development | ||||||||
| Selling, general and administrative expenses | ||||||||
| Total Costs and Expenses | ||||||||
| INCOME FROM OPERATIONS | ||||||||
| Other income and (expenses) | ||||||||
| Interest Expense | ( | ) | ( | ) | ||||
| Investment income – related party | ||||||||
| Investment income | ||||||||
| Other income – related party | ||||||||
| Other income | ||||||||
| Income Before Provision for Income Taxes and Noncontrolling Interests | ||||||||
| Provision for income taxes | ( | ) | ( | ) | ||||
| Consolidated Net Income | ||||||||
| Net Income Noncontrolling Interests | ( | ) | ( | ) | ||||
| Net Income – Attributable to FONAR | $ | $ | ||||||
| Net Income Available to Common Stockholders | $ | $ | ||||||
| Net Income Available to Class A Non-Voting Preferred Stockholders | $ | $ | ||||||
| Net Income Available to Class C Common Stockholders | $ | $ | ||||||
| Basic Net Income Per Common Share Available to Common Stockholders | $ | $ | ||||||
| Diluted Net Income Per Common Share Available to Common Stockholders | $ | $ | ||||||
| Basic and Diluted Income Per Share – Class C Common | $ | $ | ||||||
| Weighted Average Basic Shares Outstanding – Common Stockholders | ||||||||
| Weighted Average Diluted Shares Outstanding _ Common Stockholders | ||||||||
| Weighted Average Basic and Diluted Shares Outstanding _Class C Common | ||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| Page 8 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
| For the Three Months Ended December 31, 2024 | ||||||||||||||||||||||||||||||||
| Common Stock |
Common Stock Outstanding (Shares) | Paid-in
capital in excess of par value | Accumulated Deficit | Treasury Stock | Treasury Stock (Shares) | Non Controlling Interests | Total | |||||||||||||||||||||||||
| Balance – September 30, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||
| Net income | — | — | ||||||||||||||||||||||||||||||
| Purchase of Treasury stock | — | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Cancellation of Treasury stock | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Sale - Non controlling interests | — | — | ||||||||||||||||||||||||||||||
| Distributions - Non controlling interests | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Income - Non controlling interests | — | — | ||||||||||||||||||||||||||||||
| Balance – December 31, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| Page 9 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
For the Three Months Ended December 31, 2023
| Common Stock | Common Stock Outstanding (Shares) | Paid-in
capital in excess of par value | Accumulated Deficit | Treasury Stock | Treasury Stock (Shares) | Non Controlling Interests | Total | |||||||||||||||||||||||||
| Balance – September 30, 2023 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||
| Net income | — | — | ||||||||||||||||||||||||||||||
| Purchase of Treasury stock | — | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Cancellation of shares | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Distributions - Non controlling interests | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Income - Non controlling interests | — | — | ||||||||||||||||||||||||||||||
| Balance – December 31, 2023 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| Page 10 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
For the Six Months Ended December 31, 2024
| ||||||||||||||||||||||||||||||||
| Common Stock | Common Stock Outstanding (Shares) | Paid-in
capital in excess of par value | Accumulated Deficit | Treasury Stock | Treasury Stock (Shares) | Non Controlling Interests | Total | |||||||||||||||||||||||||
| Balance – June 30, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||
| Net income | — | — | ||||||||||||||||||||||||||||||
| Purchase of Treasury stock | — | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Cancellation of Treasury stock | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Sale - Non controlling interests | — | — | ||||||||||||||||||||||||||||||
| Distributions - Non controlling interests | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Income - Non controlling interests | — | — | ||||||||||||||||||||||||||||||
| Balance – December 31, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| Page 11 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
For the Six Months Ended December 31, 2023
| Common Stock | Common Stock Outstanding (Shares) | Paid-in
capital in excess of par value | Accumulated Deficit | Treasury Stock | Treasury Stock (Shares) | Non Controlling Interests | Total | |||||||||||||||||||||||||
| Balance – June 30, 2023 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||
| Net income | — | — | ||||||||||||||||||||||||||||||
| Purchase of Treasury stock | — | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Cancellation of shares | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Distributions - Non controlling interests | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Income - Non controlling interests | — | — | ||||||||||||||||||||||||||||||
| Balance – December 31, 2023 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| Page 12 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
| FOR
THE SIX MONTHS ENDED DECEMBER 31, | ||||||||
| 2024 | 2023 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Consolidated Net income | $ | $ | ||||||
| Adjustments to reconcile consolidated net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Net change in operating right of use assets and lease liabilities | ( | ) | ( | ) | ||||
| Provision for credit losses | ||||||||
| Deferred tax expense | ||||||||
| Gain on sale of equipment – related party | ( | ) | ||||||
| Changes in operating assets and liabilities, net: | ||||||||
| Accounts, medical and management fee receivable(s) | ( | ) | ( | ) | ||||
| Notes receivable | ||||||||
| Notes receivable – related party | ( | ) | ||||||
| Inventories | ( | ) | ( | ) | ||||
| Prepaid expenses and other current assets | ( | ) | ||||||
| Other assets | ( | ) | ||||||
| Accounts payable | ( | ) | ( | ) | ||||
| Other current liabilities | ( | ) | ( | ) | ||||
| Financing lease liabilities | ( | ) | ( | ) | ||||
| Customer deposits | ( | ) | ( | ) | ||||
| Other liabilities | ( | ) | ( | ) | ||||
| Net cash provided by operating activities | ||||||||
| Cash Flows from Investing Activities: | ||||||||
| Purchases of property and equipment | ( | ) | ( | ) | ||||
| Proceeds from short term investments | ||||||||
| Cost of patents | ( | ) | ( | ) | ||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| Cash Flows from Financing Activities: | ||||||||
| Repayment of borrowings and capital lease obligations | ( | ) | ( | ) | ||||
| Sale of noncontrolling interest | ||||||||
| Purchase of treasury stock | ( | ) | ( | ) | ||||
| Distributions to noncontrolling interests | ( | ) | ( | ) | ||||
| Net cash used in financing activities | ( | ) | ( | ) | ||||
| Net (Decrease) Increase in Cash and Cash Equivalents | ( | ) | ||||||
| Cash and Cash Equivalents - Beginning of Period | ||||||||
| Cash and Cash Equivalents - End of Period | $ | $ | ||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| Page 13 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
Description of Business
FONAR Corporation (the “Company” or “FONAR”) is a Delaware corporation, which was incorporated on July 17, 1978. FONAR is engaged in the research, development, production and marketing of medical scanning equipment, which uses principles of Magnetic Resonance Imaging (“MRI”) for the detection and diagnosis of human diseases. In addition to deriving revenues from the direct sale of MRI equipment, revenue is also generated from our installed-base of customers through our service and upgrade programs.
FONAR, through its wholly-owned subsidiary Health Management Corporation of America (“HMCA”) provides comprehensive management services to diagnostic imaging facilities. The services provided by the Company include development, administration, leasing of office space, facilities and medical equipment, provision of supplies, staffing and supervision of non-medical personnel, legal services, accounting, billing and collection and the development and implementation of practice growth and marketing strategies.
Effective
July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business.
The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and Health
Diagnostics Management (“HDM”). Imperial Management Services, LLC contributed all of its assets (which were utilized in the
business of Health Management Corporation of America) to HDM and received a
Basis of Presentation
These unaudited condensed consolidated financial statements for the period ended December 31, 2024 have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission pertaining to interim financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024, from which the accompanying balance sheet at June 30, 2024 was derived. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments considered necessary for a fair presentation of the interim financial information have been included and are of a normal recurring nature. The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the disclosure and reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.
| Page 14 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation (Continued)
The Company evaluates theses estimates and judgements on an ongoing basis. The Company bases estimates and judgements on historical experience and on various other factors that are believed to be reasonable under the circumstances. The results of operations for any interim period are not necessarily indicative of the results of operations for a full year.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively, the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.
Revenue Recognition
The Company’s revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. The Company’s performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than the Company’s standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
The Company’s patient fee revenue, net of contractual allowances and discounts for the three and six months ended December 31, 2024 and 2023 are summarized in the following table:
| Schedule of patient fee revenue - net | ||||||||
| For
the Three Months Ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Commercial Insurance/Managed Care | $ | $ | ||||||
| Medicare/Medicaid | ||||||||
| Workers’ Compensation/Personal Injury | ||||||||
| Other | ||||||||
| Patient Fee Revenue, net of contractual allowances and discounts | $ | $ | ||||||
| Page 15 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
| Revenue Recognition (Continued) | For
the Six Months Ended December 31, | |||||||
| 2024 | 2023 | |||||||
| Commercial Insurance/ Managed Care | $ | $ | ||||||
| Medicare/Medicaid | ||||||||
| Workers’ Compensation/Personal Injury | ||||||||
| Other | ||||||||
| Patient Fee Revenue, net of contractual allowances and discounts | $ | $ | ||||||
Management and other fee receivable
HMCA generates revenues from providing comprehensive management services, including development, administration, accounting, billing and collection services, together with office space, medical equipment, supplies and non-medical personnel to its clients. Revenues are in the form of fees which are earned under annual management contracts with HMCA clients. Management fee receivable is related to the management fees outstanding from the related and non-related professional corporations (“PCs”) under the management agreements.
Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC Topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the converted method in calculating diluted income per share for the three and six months ended December 31, 2024 and 2023.
Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three and six months ended December 31, 2024 and 2023, diluted EPS for common shareholders includes shares upon conversion of Class C Common.
| Page 16 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Earnings Per Share (Continued)
| Schedule of earning per share | ||||||||||||||||||||||||
| Three
months ended December 31, 2024 | Three
months ended December 31, 2023 | |||||||||||||||||||||||
| Total | Common Stock | Class
C Common Stock | Total | Common Stock | Class
C Common Stock | |||||||||||||||||||
| Basic | ||||||||||||||||||||||||
| Numerator:
Net income available to common stockholders | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| Denominator: | ||||||||||||||||||||||||
| Weighted average shares outstanding | ||||||||||||||||||||||||
| Basic income per common share | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| Diluted | ||||||||||||||||||||||||
| Denominator:
Weighted average shares outstanding | ||||||||||||||||||||||||
| Convertible Class C Stock | ||||||||||||||||||||||||
| Total Denominator for diluted earnings per share | ||||||||||||||||||||||||
| Diluted income per common share | $ | $ | $ | $ | ||||||||||||||||||||
| Six
months ended December 31, 2024 | Six
months ended December 31, 2023 | |||||||||||||||||||||||
| Total | Common Stock | Class
C Common Stock | Total | Common Stock | Class
C Common Stock | |||||||||||||||||||
| Basic | ||||||||||||||||||||||||
| Numerator:
Net income available to common stockholders | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| Denominator: | ||||||||||||||||||||||||
| Weighted average shares outstanding | ||||||||||||||||||||||||
| Basic income per common share | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| Diluted | ||||||||||||||||||||||||
| Denominator:
Weighted average shares outstanding | ||||||||||||||||||||||||
| Convertible Class C Stock | ||||||||||||||||||||||||
| Total Denominator for diluted earnings per share | ||||||||||||||||||||||||
| Diluted income per common share | $ | $ | $ | $ | ||||||||||||||||||||
| Page 17 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Correction of immaterial errors
In
conjunction with preparing its interim financial statements for the three and six months ended December 31, 2024, the Company determined
that its calculation of Right to Use Assets and Operating Lease Liabilities at the end of the past two annual periods and at September
30, 2024 and 2023 contained three immaterial errors. The Company evaluated the errors, both qualitatively and quantitatively, and determined
that no prior interim or annual periods were materially misstated. The Company then evaluated whether the cumulative amount of the misstatement
was material to its projected fiscal 2025 results of operations, and determined the cumulative amount was not material. Therefore, the
Condensed Consolidated Financial Statements for the six and three months ended December 31, 2024 include an out-of-period correction
of the following three items; a) a reclass of a software license of $
Recent Accounting Standards
In December 2023, The Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which requires the annual financial statements to include consistent categories and great disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with a retrospective option. The Company is currently evaluating the effect that the adoption of ASU 2023-09 will have on its disclosures.
In November 2023, FASB issued ASU 2023-07, “Segment Reporting (Topic 280)”, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (“CODM”) as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable segment entities, permit more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the title and position of the CODM. The effective date for public entities is for fiscal years beginning after December 15, 2023 and interim periods with fiscal years beginning after December 15, 2024. The Company is expected to adopt the new disclosures as required and are currently evaluating the impact on the related disclosures.
| Page 18 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Recent Accounting Standards
FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2024 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2024 or 2023, and it does not believe that any of those standards will have a significant impact on our unaudited consolidated condensed financial statements at the time they become effective.
NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE
Receivables, net are comprised of the following at December 31, 2024, and June 30, 2024:
| Schedule of financing receivable noncurrent allowance for credit loss | ||||||||||||
| December 31, 2024 | ||||||||||||
| Gross Receivable | Allowance for credit losses | Net | ||||||||||
| Accounts receivable | $ | $ | $ | |||||||||
| Accounts receivable - related party | $ | $ | $ | |||||||||
| Medical receivable | $ | $ | $ | |||||||||
| Management and other fees receivable | $ | $ | $ | |||||||||
| Management and other fees receivable from related medical practices (“PC’s”) | $ | $ | $ | |||||||||
| June 30, 2024 | ||||||||||||
| Gross Receivable | Allowance for credit losses | Net | ||||||||||
| Accounts receivable | $ | $ | $ | |||||||||
| Medical receivable | $ | $ | $ | |||||||||
| Management and other fees receivable | $ | $ | $ | |||||||||
| Management and other fees receivable from related medical practices (“PC’s”) | $ | $ | $ | |||||||||
The Company’s customers are concentrated in the healthcare industry.
| Page 19 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (CONTINUED)
Accounts Receivable
Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company has established a current expected credit loss (“CECL”) to address the risk that a portion of these fees will not be paid. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided.
Long Term-Accounts Receivable
Long
term-accounts receivable balances at December 31, 2024 and June 30, 2024 amounted to approximately $
| Schedule of future revenue | |||||
| 2026 | $ | ||||
| 2027 | |||||
| 2028 | |||||
| 2029 | |||||
| Total | $ |
Medical Receivables
Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. Medical receivables are recorded at net realizable value based on the estimated amounts the Company expects to receive from patients and third-party payors. The medical receivable is reduced by contractual adjustments based on the historical experience with each payor class at each location.
| Page 20 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (CONTINUED)
Management and Other Fees Receivable
Management fees receivable is related to management fees outstanding from the related and non related PCs under management agreements. The Company has established a CECL to address the risk that a portion of the contractually obligated management fees receivable from the PCs may not be paid. The PC’s may be limited in their ability to pay the full management fee receivable if they do not collect sufficient expected fees from third-party payers and patients. The Company’s management fees are collateralized, individually and collectively, by the assets of the PCs. The CECL is determined based on the difference between the management fee receivable and the current amount of outstanding fees estimated to be collected by the PCs.
Management and Other Fees Receivable (Continued)
The
Company’s considerations into the estimate of the PC’s fee collection is based on a combination of factors. As each management
agreement specifies the Company’s ultimate collateral for unpaid management fees are the patient fee receivables owned by each
PC, the Company considers the historical loss rates to pools of receivables with similar risks characteristics, aging of the patient
fee receivables, and the financial condition of each PC. In addition, the Company subjectively adjusts its estimated expected credit
losses for current and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulation.
The Company also incorporates qualitative factors, such as changes in the nature and volume of receivables, regulatory changes, and other
relevant factors. Specifically, insurance carriers covering automobile no-fault and workers compensation claims incur longer payment
cycles and rigorous informational requirements and certain other disallowed claims. Approximately
The Company combines an objective and subjective loss-rate methodology to estimate expected credit losses based on the collateral owned by each PC. This involves objectively using historical loss rates to pools of receivables with similar risk characteristics (i.e. various insurance payors) and then subjectively adjusting for current and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulation. The Company also incorporates qualitative factors, such as changes in the nature and volume of the receivables, regulatory changes, and other relevant factors. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to the Company.
| Page 21 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (CONTINUED)
Net
revenues from management and other fees charged to the related PCs accounted for approximately
NOTE 4 – OPERATING AND FINANCING LEASES
The Company accounts for its various operating leases in accordance with Accounting Standards Codification (ASC) 842 – “Leases”, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company most common initial term varies in length from 2 to 19 years. Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Our incremental borrowing rate (“IBR”) used to discount the stream of operating lease payments is closely related to the interest rates available to the Company.
A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2024 is as follows:
| Schedule of lessee operating leases liability maturity | |||||||||
| Twelve
Months Ending December 31, | Operating
Lease Payments | Financing Lease Payments | |||||||
| 2025 | $ | $ | |||||||
| 2026 | |||||||||
| 2027 | |||||||||
| 2028 | |||||||||
| 2029 | |||||||||
| Thereafter | |||||||||
| Present value discount | ( | ) | ( | ) | |||||
| Total lease liability | $ | $ | |||||||
| Page 22 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 4 – OPERATING AND FINANCING LEASES (CONTINUED)
Weighted Average Remaining Lease Term
| Schedule of weighted average remaining lease term | ||||
| Operating leases - years | ||||
| Finance lease - years | ||||
| Weighted Average Discount Rate | ||||
| Operating leases | % | |||
| Finance lease | % |
The components of lease expense were as follows:
| Components of lease expense | ||||||||
| For the six months ended Dec.31, | ||||||||
| 2024 | 2023 | |||||||
| Operating lease cost | $ | $ | ||||||
| Finance lease cost: | ||||||||
| Depreciation of leased equipment | $ | $ | ||||||
| Interest on lease liabilities | ||||||||
| Total finance lease cost | $ | $ | ||||||
Supplemental cash flow information related to leases was as follows:
| Supplemental cash flow information related to leases | ||||||||
| For the six months ended Dec. 31, | ||||||||
| Cash paid for amounts included in the measurement of lease liabilities: | 2024 | 2023 | ||||||
| Operating cash flows from operating leases | $ | $ | ||||||
| Financing cash flows from financing leases | $ | $ | ||||||
| Right-of-use and equipment assets obtained in exchange for lease obligations: | ||||||||
| Operating leases | $ | $ | ||||||
| Page 23 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 5 - INVENTORIES
Inventories included in the accompanying condensed consolidated balance sheets consist of the following:
| Schedule of inventories | ||||||||
| December
31, 2024 | June
30, 2024 | |||||||
| Purchased parts, components and supplies | $ | $ | ||||||
| Work-in-process | ||||||||
| Total Inventories | $ | $ | ||||||
NOTE 6 – OTHER INTANGIBLE ASSETS
Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:
| Schedule of other intangible assets | ||||||||||||||||
| Weighted average useful lives | Gross carrying amount – December 31, 2024 | Accumulated amortization – December 31, 2024 | Net carrying amount – December 31, 2024 | |||||||||||||
| Capitalized software development costs | $ | $ | ( | ) | $ | |||||||||||
| Software License | ( | ) | ||||||||||||||
| Patents and copy rights | ( | ) | ||||||||||||||
| Non-compete | ( | ) | ||||||||||||||
| Customer relationships | ( | ) | ||||||||||||||
| Total | $ | $ | ( | ) | $ | |||||||||||
| Page 24 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 6 – OTHER INTANGIBLE ASSETS (CONTINUED)
| Weighted average useful lives | Gross carrying amount – June 30, 2024 | Accumulated amortization | Net carrying amount | |||||||||||||
| Capitalized software development costs | $ | $ | ( | ) | $ | |||||||||||
| Patents and copy rights | ( | ) | ||||||||||||||
| Non-compete | ( | ) | ||||||||||||||
| Customer relationships | ( | ) | ||||||||||||||
| Total | $ | $ | ( | ) | $ | |||||||||||
Amortization
of patents and copyrights for the three months ended December 31, 2024 and 2023 amounted to $
Amortization
of customer relationships for the three months ended December 31, 2024 and 2023 amounted to $
Amortization
of patents and copyrights for the six months ended December 31, 2024 and 2023 amounted to $
Amortization
of customer relationships for the six months ended December 31, 2024 and 2023 amounted to $
Amortization expense for reach of the next five years and thereafter as of December 31, 2024 are as follows:
| 2025 | |||||
| 2026 | |||||
| 2027 | |||||
| 2028 | |||||
| 2029 | |||||
| Thereafter | |||||
| Total | $ |
| Page 25 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 7 – OTHER CURRENT LIABILITIES
Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following:
| Schedule of other current liabilities | ||||||||
| December
31, 2024 | June
30, 2024 | |||||||
| Accrued salaries, commissions and payroll taxes | $ | $ | ||||||
| Sales tax payable | ||||||||
| Federal and state income taxes payable | ||||||||
| Self-funded health insurance reserve | ||||||||
| Software Licenses | ||||||||
| Other general and administrative expenses | ||||||||
| Other Current Liabilities | $ | $ | ||||||
NOTE 8 - SEGMENT AND RELATED INFORMATION
The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company’s 10-K as of June 30, 2024. All inter segment sales are market-based. The Company evaluates performance based on income or loss from operations.
Summarized financial information concerning the Company’s reportable segments is shown in the following table:
| Schedule of summarized segment financial information | ||||||||||||
| Manufacturing and Service of MRI Equipment | Management of Diagnostic Imaging Centers | Totals | ||||||||||
| For the three months ended December 31, 2024 | ||||||||||||
| Net revenues from external customers | $ | $ | $ | |||||||||
| Inter-segment net revenues | $ | $ | $ | |||||||||
| (Loss) Income from operations | $ | ( | ) | $ | $ | |||||||
| Depreciation and amortization | $ | $ | $ | |||||||||
| Capital expenditures | $ | $ | $ | |||||||||
| For the three months ended December 31, 2023 | ||||||||||||
| Net revenues from external customers | $ | $ | $ | |||||||||
| Inter-segment net revenues | $ | $ | $ | |||||||||
| (Loss) Income from operations | $ | ( | ) | $ | $ | |||||||
| Depreciation and amortization | $ | $ | $ | |||||||||
| Capital expenditures | $ | $ | $ | |||||||||
| Page 26 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 8 - SEGMENT AND RELATED INFORMATION (CONTINUED)
| Manufacturing and Service of MRI Equipment | Management of Diagnostic Imaging Centers | Totals | ||||||||||
| For the six months ended December 31, 2024 | ||||||||||||
| Net revenues from external customers | $ | $ | $ | |||||||||
| Inter-segment net revenues | $ | $ | $ | |||||||||
| (Loss) Income from operations | $ | ( | ) | $ | $ | |||||||
| Depreciation and amortization | $ | $ | $ | |||||||||
| Capital expenditures | $ | $ | $ | |||||||||
| Manufacturing and Service of MRI Equipment | Management of Diagnostic Imaging Centers | Totals | ||||||||||
| For the six months ended December 31, 2023 | ||||||||||||
| Net revenues from external customers | $ | $ | $ | |||||||||
| Inter-segment net revenues | $ | $ | $ | |||||||||
| (Loss) Income from operations | $ | ( | ) | $ | $ | |||||||
| Depreciation and amortization | $ | $ | $ | |||||||||
| Capital expenditures | $ | $ | $ | |||||||||
NOTE 9 – SUPPLEMENTAL CASH FLOW INFORMATION
During
the six months ended December 31, 2024 and December 31, 2023, the Company paid $
During
the six months ended December 31, 2024 and December 31, 2023, the Company paid $
During
the six months ended December 31, 2024 and December 31, 2023, the Company obtained right-of-use and equipment assets in exchange for
lease obligations of $
During
the three months ended December 31, 2024, the Company sold a
| Page 27 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 10 – COMMITMENTS AND CONTINGENCIES
Litigation
The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company.
In the ordinary course of its business, the Company is a party to various lawsuits arising from the operations at the MRI sites and other insurance related matters, which are generally handled by the Company’s insurance carriers. Management believes, based in part on the advice counsel, that the ultimate resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.
There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2024.
Other Matters
On
September 13, 2022, the Company adopted a stock repurchase plan. The plan has no expiration date and cannot determine the number of shares
which will be repurchased. On September 26, 2022, the Board of Directors has approved up to $
The
Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third-party insurer to limit the maximum
potential liability for individual claims to $
The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the periods covered by this report.
| Page 28 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 11 - INCOME TAXES
In
accordance with ASC 740-270, “Income Taxes – Interim Reporting”, the Company is required at the end of each interim
period to determine the best estimate of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The
resulting tax expense (or benefit) is adjusted for the tax effect of specific events, if any, required to be discretely recognized in
the interim period as they occur. For the six months ended December 31, 2024 and 2023, the Company recorded income tax expense of $
ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC Topic 740. The Company believes there are no uncertain tax positions in prior year tax filings and therefore it has not recorded a liability for unrecognized tax benefits.
The
Company recorded a deferred tax asset of $
The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2020.
Future ownership changes as determined under Section 382 of the Internal Revenue Code could further limit the utilization of net operating loss carryforwards. As of December 31, 2024, no such changes in ownership have occurred.
The
Inflation Reduction Act (“IRA”) was enacted on August 16, 2022. The IRA includes provisions imposing a
| Page 29 |
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 12 – RELATED PARTY TRANSACTIONS
Tallahassee
Magnetic Resonance Imaging, Inc. Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, Inc. (all related medical practices)
entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which
have arisen under each individual management agreement. During the six months ended December 31, 2024 and 2023, the net revenues received
by the Company was $
Bensonhurst
MRI Limited Partnership (“Bensonhurst”), in which the CEO and President of the Company holds an interest, is party to an
agreement with the Company for the service and maintenance of its Upright MRI Scanner for a price of $
Radian
Healthcare Management, LLC (“Radian”), which is owned by the son-in-law of the CEO and President of the Company provided
the Company with personnel recruitment of new employees at a fee of approximately $
On
December 31, 2023, the Company entered into an agreement with Magnetic Resonance Management, LLC (“MRM”) for the sale of
a MRI scanner. MRM is owned by the CEO and President of the Company. The sales price of the equipment was $
NOTE 13 – SUBSEQUENT EVENTS
The Company has evaluated events that occurred subsequent to December 31, 2024 and through the date the condensed consolidated financial statements were issued.
In
the subsequent period up to the date of filing, the Company repurchased shares
of common stock at a cost of $
| Page 30 |
FONAR CORPORATION AND SUBSIDIARIES
Item 2. – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, item 1 of the Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto for the year ended June 30, 2024 included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed with the U.S. Securities and Exchange Commission (SEC) on September 27, 2024.
Forward Looking Statements
Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on current expectations that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the expansion of business. These assumptions involve judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately. Many of these assumptions involve factors which are beyond our control. Although we believe that our assumptions underlying these forward-looking statements are reasonable, any of the assumptions could prove inaccurate. Therefore, there can be no assurance that the forward-looking statements included in this Quarterly Report will be accurate. In light of the significant uncertainties inherent in these forward-looking statements, the inclusion of such information should not be considered a representation by us or any other person that our objectives will be achieved.
For the six-month period ended December 31, 2024, we reported a net income of $6.3 million on revenues of $50 million as compared to net income of $10.0 million on revenues of $51.2 million for the six-month period ended December 31, 2023. Operating income decreased from $11.5 million for the six-month period ended December 31, 2023 to $7.1 million for the six month period ended December 31, 2024. We have taken a significant reserve against accounts receivable that are attributable to American Transit Insurance Company, a New York based motor vehicle insurer who has recently indicated that they are approaching insolvency. We are monitoring the situation for new developments. We may need to take additional reserves in the future if this carrier is placed into receivership by the New York Department of Financial Services. Revenues from product sales and service and repair fees increased from $3.9 million for the first six months of fiscal 2024 as compared to $4.0 million for the first six months of fiscal 2025.
For the-three month period ending December 31, 2024, we reported a net income of $2.3 million on revenues of $25.0 million as compared to net income of $4.6 million on revenues of $25.4 million for the three-month period ended December 31, 2023.
The revenue decrease, from $51.2 million for the first six months of fiscal 2024 to $50.0 million for the first six months of fiscal 2025, was primarily due to decreases in patient fee revenue of $1.5 million, from $16.9 million for the first six months of fiscal 2024 to $15.4 million for the first six months of fiscal 2025.
| Page 31 |
FONAR CORPORATION AND SUBSIDIARIES
The revenue decrease from $25.4 million for the three-month period ended December 31, 2023 to $25.0 million for the three-month period ended December 31, 2024, was primarily due to decreases in patient revenue of $300, from $8.2 million for the three-month period ended December 31, 2023 to $7.9 million for the three-month period ended December 31, 2024. Revenues from product sales and service and repair fees decreased slightly from $1.9 million for the three-month period ended December 31, 2023 to $1.8 million for the three-month period ended December 31, 2024.
During the first half of fiscal 2025, the aggregate number of scans performed by the sites we own decreased to 26,961 scans from 28,214 scans in the first half of fiscal 2024. This decrease was due to increase competition in certain areas along with hurricane related closures. During the first half of fiscal 2025, the aggregate number of scans performed by the sites we manage increased to 79,207 scans from 73,776 scans in the first half of fiscal 2024. This increase was due to improvements in our information technology systems, increased shift coverage, and increased capacity from our recent equipment expansions.
The combination of our revenues decreasing along with our costs and expenses increasing caused our operating income to decrease to $7.0 million for the six months ended December 31, 2024 as compared to $11.5 million for the six months ended December 31, 2023. In terms of percentages, costs and expenses increased 7.5% to $42.8 million for the first six months of fiscal 2025 as compared to $39.8 million for the first six months of fiscal 2024, while revenues decreased 2.6% to $50.0 million for the first six months of fiscal 2025 as compared to $51.2 million for the first six months of fiscal 2024. The decrease in revenue can be attributable to a decrease in patient fee revenues of $1.5 million from the six-month period ending December 31, 2024 as compared to $16.9 million from the six-month period ending December 31, 2023. The increase in costs and expenses can be attributable to additional reserves of $923 which was mainly due to increase reserves for the outstanding balance of American Transit Insurance along a new outside billing for the collection of our commercial insurance which commenced on January 1, 2024. The costs of the new billing contract in the six-month period ended was $421.
The combination of our revenues decreasing along with our costs and expenses increasing caused our operating income to decrease to $2.6 million for the three-month period ended December 31, 2024 as compared to $4.9 million for the three months ended December 31, 2023. In terms of percentages, costs and expenses increased 9.3% to $22.4 million for the three months ended December 31, 2024 as compared to $20.5 million for the three months ended December 31, 2023, while revenues decreased 1.7% to $25.0 million for the three months end December 31, 2024 as compared to $25.4 million for the three months ended December 31, 2023.
FONAR’s wholly-owned subsidiary, Health Management Corporation of America (“HMCA”), has the controlling interest in Health Diagnostics Management, LLC (“HDM”). HMCA presently has a direct ownership interest of 70.6% in HDM, and the investors in HDM have a 29.4% ownership interest. During the quarter ended December 31, 2024, the Company sold non-controlling interests to a minority shareholder for $132,000. The management of the diagnostic imaging centers business segment is being conducted by HDM, operating under the name “Health Management Company of America”. For the sake of simplicity, HMCA, and HDM are referred to as “HMCA”, unless otherwise indicated.
Critical Accounting Estimates
There
have been no material changes in our Critical Accounting Estimates from the information provided in the “Critical Accounting Estimates”
section of “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations” in
our Annual Report on Form 10-K for the fiscal year ended June 30, 2024.
| Page 32 |
FONAR CORPORATION AND SUBSIDIARIES
Results of Operations
We operate in two industry segments: the manufacture and servicing of medical (MRI) equipment, which is conducted by FONAR and diagnostic facilities management services, which is conducted through HMCA.
Consolidated
For the first six months of fiscal 2025, our consolidated net revenues decreased by 2.6% to $50.0 million from $51.2 million for the first six months of fiscal 2024, and total costs and expenses increased by 7.8% to $42.9 million from the first six months of fiscal 2025 as compared to $39.8 million for the first six months of fiscal 2024, respectively. As a result, our operating income decreased to $7.0 million in the first six months of fiscal 2025 as compared to $11.5 million in the first six months of fiscal 2024. A decrease in selling, general and other administrative costs in particular resulted in cost and expenses increase at a much lower percentage as compared to the increase in net revenues.
Selling, general and administrative expenses increased to $12.1 million in the first six months of fiscal 2025 from $10.5 million in the first three months of fiscal 2024. This increase in selling, general and administrative expenses was due to additional reserves taken in the current period of $923 mainly for the uncertainty of the collection of American Transit Insurance coupled with the new outside billing contract that accounts for $421.
Research and development expenses decreased by 22.7% to $683,000 for the first six months of fiscal 2025 from $883,000 for the first six months of fiscal 2024.
Interest expense in the first six months of fiscal 2025 decreased by 63.2% to $14,000 from $38,000 in the first six months of fiscal 2024.
The results of operations for the first six months of fiscal 2025 reflect a decrease in revenues from management, patient and other fees, as compared to the first six months of fiscal 2024 ($45.9 million for the first six months of fiscal 2025 as compared to $47.3 million for the first six months of fiscal 2024), coupled with an increase in the total cost and expenses ($42.9 million for the first six months of fiscal 2025 as compared to $39.8 million for the first six months of fiscal 2024). Revenues were 8.0% from the MRI equipment segment and 92.0% from HMCA, for the first six months of fiscal 2025, as compared to 7.6% from the MRI equipment segment and 92.4% from HMCA for the first six months of fiscal 2024.
We are committed to improving our operating results and dealing with the challenges posed by legislative and regulatory requirements. Nevertheless, factors beyond our control, such as the timing and rate of market growth, economic conditions, the availability of credit and payor reimbursement rates, or unexpected expenditures and the timing of such expenditures, make it difficult to forecast future operating results.
Medicare reimbursement rates for MRI scans continue to see year over year reductions. This also results in a reduction in the reimbursement rates by commercial insurers and government programs which tie their reimbursement rates to the Medicare rates. The patient volume of the scanning centers we manage or own has enabled us to maintain healthy operating results in spite of these reductions.
| Page 33 |
FONAR CORPORATION AND SUBSIDIARIES
Our Upright® MRI (also referred to as the Stand-Up® MRI), together with our works-in-progress, are intended to significantly improve our competitive position.
The Upright® MRI scanner, which operates at 6000 gauss (.6 Tesla) field strength, allows patients to be scanned while standing, sitting, reclining and in multiple flexion and extension positions. It is common in visualizing the spine that abnormalities are visualized in some positions and not others. This enables surgical corrections that heretofore would not have been addressable for lack of visualizing the symptom causing the pathology and therefore, in general enables the treating physician to achieve a better outcome for his patient. A floor-recessed elevator brings the patient to the height appropriate for the targeted image region. A custom-built multi-position adjustable bed will allow patients to sit or lie on their backs, sides or stomachs at any angle. This allows the MRI technologist to ask the patient to position himself/herself in the exact position that generates pain so that images of the patient in the position that explicitly generates the patient’s pain can be nailed down. Full-range-of-motion studies of the joints in virtually any direction are possible, a particularly promising feature for sports injuries.
Medical Equipment - Manufacturing and Service of MRI Equipment
Revenues from MRI product sales decreased to $145,000 for the first six months of fiscal 2025 from $219,000 for the first six months of fiscal 2024. Costs related to product sales increased from $405,000 for the six month period ended December 31, 2023 to $442,000 for the six month period ended December 31, 2024 Revenues from MRI product sales decreased to $25 for the three months ending December 31, 2024 from $55 for the three months ending December 31, 2023. Costs related to product sales decreased from $302 for the three months ending December 31, 2023 as compared to $221 for the three months ended December 31, 2024, Economic uncertainty and lower reimbursement rates for MRI scans, have depressed the market for our MRI scanner products, notwithstanding our scanners’ unique technological capabilities (e.g., multi-positional scanning). Due to the low sales volumes of our MRI product, period to period comparisons are not necessarily indicative of any trends.
Service revenues increased to $3.8 million for the six-month period ended December 31, 2024 from $3.7 million for the six-month period ended December 31, 2023. Service revenues remained constant at $1.8 million for the three month periods ending December 31, 2024 and 2023.
Costs relating to providing service were $2.1 million in the first six months of fiscal 2025 as compared to $1.7 million in the first six months of fiscal 2024. Costs relating to providing service were $1.1 million for the three month period ended December 31, 2024 as compared to $796 for the three months ended December 31, 2023. The increase is attributable to spending on our subsidiary dedicated to the maintenance and repair of non-FONAR MRI equipment, and various costs related to the marketing and distribution of SwiftMR™ software. Because of our ability to monitor the performance of customers’ scanners from our facilities in Melville, New York on a daily basis and to detect and repair any irregularities before more serious and costly problems develop, we have been able to contain our costs of providing service.
There were approximately $314,000 in foreign revenues for the first six months of fiscal 2025 as compared to $263,000 for the first six months of fiscal 2024. We do not regard this as a material trend, but as part of a normal although sometimes volatile variation resulting from low volumes of foreign sales.
| Page 34 |
FONAR CORPORATION AND SUBSIDIARIES
Revenues for the medical equipment segment increased to $4.0 million for the first six months of fiscal 2025 from $3.9 million for the first six months of fiscal 2024. Operating losses for our medical equipment segment increased to an operating loss of $2.3 million, for the first six months of fiscal 2025 as compared to an operating loss of $1.7 million for the first six months of fiscal 2024.
Revenues for the medical equipment segment decreased to $1.8 million for the three months ending December 31, 2024 from $1.9 million for the three months ending December 31, 2023. Operating losses for our medical equipment segment increased to an operating loss of $1.3 million, for the three months ending December 31, 2024 as compared to an operating loss of $993 for the three months ending December 31, 2023.
Management of Diagnostic Imaging Centers
HMCA revenues decreased in the first six months of fiscal 2025 by 2.9% to $45.9 million from $47.3 million for the first six months of fiscal 2024. The percentage of our revenues derived from our diagnostic facilities management segment relative to the percentage of our total revenues decreased slightly to 92.0% for the first three months of fiscal 2025, from 92.4% for the first three months of fiscal 2024.
HMCA revenues decreased in the three months ending December 31, 2024 by 1.8% to $23.1 million from $23.5 million for the three months ending December 31, 2023. The percentage of our revenues derived from our diagnostic facilities management segment relative to the percentage of our total revenues remained constant to 92.7% for the three months ending December 31, 2024 and 2023.
We completed the installation of a new scanner in the Naples, Florida location at the end of the first quarter of fiscal 2025. We now manage or own a total of 43 MRI scanners. Twenty-five (25) MRI scanners are located in New York and eighteen (18) are located in Florida. HMCA experienced an operating income of $9.5 million for the first six months of fiscal 2025 compared to operating income of $13.2 million for the first six months of fiscal 2024. The decrease in operating revenue is a combination of increased expenses and reduced patient fee revenue at the HMCA-owned Florida sites. Expenses increased in the form of staffing costs, equipment repair costs, and helium replacement costs. Although scan volume was up in the aggregate, a decrease in patient fee revenue at the HMCA-owned Florida sites also contributed to the reduction on operating income.
The ability of HMCA to maintain its profitability is principally due to HMCA’s success in marketing the scanning services of the facilities managed or owned by HMCA, notwithstanding the decrease in reimbursement rates paid for MRI scans by insurers, Medicare and other government programs. The reductions in reimbursement rates are not unique to HMCA or HMCA’s clients but are being experienced by the industry in general.
HMCA’s cost of revenues for the first six months of fiscal 2025 increased to $27.6 million as compared to $26.4 million for the first six months of fiscal 2024. HMCA’s cost of revenues for the three months ending December 31, 2024 increased to $14.0 million from $13.4 million for the three months ending December 31, 2023. This increase is the result of increased expenses from scanning volume at our HMCA-managed sites, where revenues are fixed pursuant to the management agreements.
| Page 35 |
FONAR CORPORATION AND SUBSIDIARIES
Liquidity and Capital Resources
Cash and cash equivalents, and short term investments decreased from $56.5 million at June 30, 2024 to $53.7 million at December 31, 2024.
Cash provided by operating activities for the first six months of fiscal 2025 was $3.9 million. Cash provided by operating activities was attributable principally to net income of $6.2 million, adjusted for depreciation and amortization of $2.3 million, provision for credit losses of $1.3 million, and deferred income tax of $1.1 million, offset primarily by an increase in accounts, management fee receivables and medical receivables of $435,000, and a decrease in other current liabilities of $4.6 million.
Cash used in investing activities for the first six months of fiscal 2025 was $2.6 million. Cash used in investing activities during the first six months of fiscal 2025 consisted of patent costs of $20,000, the purchase of property and equipment of $2.6 million, offset set by proceeds from short-term investments of $15,000.
Cash used in financing activities for the first six months of fiscal 2025 was $4.1 million. The principal uses of cash in financing activities during the first six months of fiscal 2025 were the repayment of principal on long-term debt and capital lease obligations of $58,000, the purchase of treasury stock of $1.3 million, distributions to non-controlling interests of $2.8 million offset by the sale of non-controlling interest of $132,000.
Total liabilities decreased by 14.7% to $49.0 million at December 31, 2024 from $57.5 million at June 30, 2024. “Other” current liabilities decreased by 50.7% to $3.9 million at December 31, 2024 from $7.9 million at June 30, 2024. The current portion of our service contract liabilities decreased by 10.4% to $3.5 million at December 31, 2024 as compared to $3.9 million at June 30, 2024. The long-term portion of operating lease liability decreased from $37.5 million at June 30, 2024 to $34.9 million at December 31, 2024.
As of December 31, 2024, the total of $3.9 million in “other” current liabilities included accrued salaries and payroll taxes of $1.5 million, sales taxes payable of $183,000, software license of $252,000 and other general and administrative expenses of $1.7 million.
Our working capital increased to $125.4 million at December 31, 2024 from $122.5 million at June 30, 2024. This resulted from a decrease in current assets ($140.3 million at June 30, 2024 as compared to $137.6million at December 31, 2024), and a decrease in current liabilities from $17.9 million at June 30, 2024 to $12.2 million at December 31, 2024.
The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry, and tax planning strategies in making this assessment. At the present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for separate state net operating losses that are not expected to be fully utilized. A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of any portion or all of the valuation allowance.
| Page 36 |
FONAR CORPORATION AND SUBSIDIARIES
The Company’s effective income tax rate is based on expected income, statutory rates and tax planning opportunities available in the various jurisdictions in which it operates. For interim financial reporting, the Company estimates the annual income tax rate based on projected taxable income for the full year and records a quarterly income tax provision or benefit in accordance with the anticipated annual rate. The Company refines the estimates of the year’s taxable income on a periodic basis as new information becomes available, including actual year-to-date financial results. This continual estimation process often results in a change to the expected effective income tax rate for the year. When this occurs, the Company adjusts the income tax provision during the quarter in which the change in estimate occurs so that the year-to-date provision reflects the expected income tax rate. Significant judgment is required in determining the effective tax rate and in evaluating tax positions.
FONAR is committed to making the following significant capital expenditures for the remainder of the 2025 fiscal year. The Company is in the process of placing an additional scanner in a current location in New York and anticipates it to be completed by the fourth quarter of fiscal 2025. The estimated costs to complete this project have been estimated to be $2.0 million.
Critical to our business plan are the improvement and expansion of the MRI facilities managed or owned by HMCA, and increasing the number of scans performed at those facilities. In addition, our business plan calls for a continuing commitment to providing our customers with enhanced equipment service and maintenance capabilities and delivering state-of-the-art, innovative and high quality equipment and upgrades at competitive prices.
FONAR entered into an agreement with AIRS Medical to install its SwiftMR™ product on all FONAR Upright® scanners operating at the facilities HMCA owns or manages. FONAR will also make the AIRS SwiftMR™ product available to the installed base of FONAR scanners operating in the United States. Management believes this product improves the quality of the images produced by FONAR equipment, and provides operational efficiencies that result in additional scan volume in the scanners operated by HMCA facilities.
Management is seeking to promote wider market recognition of FONAR’s scanner products, and to increase demand for Upright® scanning at the facilities HMCA owns or manages. Given the liquidity and credit constraints in the markets, and the high level of competition in the marketplace, the sale of medical equipment has and may continue to suffer.
The Company believes that its business plan has been responsible for its profitability in the past ten consecutive fiscal years and first six months of fiscal 2025, and that its capital resources will be adequate to support operations through a year from the date of filing. The future effects on our business of healthcare legislation, the 2.3% excise tax on sales of medical equipment, reimbursement rates, public health conditions and the general economic and business climate are not known at the present time. Nevertheless, there is a possibility of adverse consequences to our business operations from these causes.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The Company maintains its funds in liquid accounts. None of our investments are in fixed rate instruments.
All of our revenue, expense and capital purchasing activities are transacted in United States dollars.
| Page 37 |
FONAR CORPORATION AND SUBSIDIARIES
Item 4. Controls and Procedures
Disclosure Controls and Procedures
We carried out an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the ‘‘Exchange Act’’). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based upon our evaluation, our chief executive officer and chief financial officer have concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2024, in ensuring that material information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the same time periods specified in the Securities and Exchange Commission rules and forms.
Changes in Internal Control over Financial Reporting
There were no changes in our system of internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
| Item 1 – Legal Proceedings: There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2024. |
Item 1A – Risk Factors: An investment in the securities of the Company is subject to various risks, the most significant of which are summarized below.
1. Reduced Reimbursement Rates. Most of our revenues are derived from our scanning center business conducted by HMCA. Our scanning center clients and the Florida facilities owned by HMCA are experiencing lower reimbursement rates from Medicare, other government programs and private insurance companies. To the extent possible, we counter these reductions by increasing scanning volume and controlling operating expenses. Inflation in the cost of both materials and labor have limited our ability to control our costs, negatively impacting our ability to maintain profitability in this business segment.
2. Inflation. Inflation has drastically increased our costs for both materials and labor. Diagnostic imaging facilities require significant amounts of capital to operate, particularly in the context of opening new diagnostic imaging centers. These increased costs make it more difficult to achieve organic growth and extend the time that a new center takes to achieve profitability. Continued costs increases, coupled with reduced reimbursement rates may threaten the profitability of our current operations and cause the cost of expansion to become prohibitively high.
| Page 38 |
FONAR CORPORATION AND SUBSIDIARIES
3. Cybersecurity threats. The healthcare industry has increasingly become a target for threat actors. Our organization relies on information technology systems and computer networks to operate. Our partners, vendors, and business associates are equally reliant on their own computer systems to provide the services that we depend on to perform core functions. Data incidents in the form of breaches, ransomware attacks, denial-of-service attacks, and a variety of other hazards could materially disrupt our operations, or the operations of our partners. In addition, the costs to respond to such incidents related to rebuilding internal systems, restoring data, responding to regulatory investigations and/or litigation could be significant. Our cybersecurity liability insurance may be inadequate to cover these losses. The cost of maintaining and improving our security technologies to protect ourselves from these threats is increasing. Risks outside of our control, such as cybersecurity attacks to our partners, vendors and business associates could threaten our ability to operate in the short term and reduce operating margins.
4. Dependence on Referrals. HMCA derives substantially all of its revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at the facilities. We depend on referrals of patients from unaffiliated physicians and other third parties to the facilities we manage or own for the services we perform. If these physicians and other third parties were to reduce the number of patients they refer or discontinue referring patients, scan volumes could decrease, which would reduce our net revenue and operating margins.
5. Pressure to Control Healthcare Costs. One of the principal objectives of health maintenance organizations and preferred provider organizations is to control the cost of healthcare services. Healthcare providers participating in managed care plans may be required to refer diagnostic imaging tests to certain providers depending on the plan in which a covered patient is enrolled. In addition, managed care contracting has become very competitive. The expansion of health maintenance organizations, preferred provider organizations and other managed care organizations in New York or Florida could have a negative impact on the utilization and pricing of services performed at the facilities HMCA manages or owns to the extent these organizations exert control over patients’ access to diagnostic imaging services, selections of the provider of such services and reimbursement rates for those services.
6. Scanning Facility Competition. The market for diagnostic imaging services is highly competitive. The facilities we manage or own compete for patients on the basis of reputation, location and the quality of diagnostic imaging services. Groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment are the principal competitors.
7. Eligibility Changes to Insurance Programs. Due to potential decreased availability of healthcare through private employers, the number of patients who are uninsured or participate in governmental programs may increase. Healthcare reform legislation will continue to increase the participation of individuals in the Medicaid program in states that elect to participate in the expanded Medicaid coverage. A shift in payor mix from managed care and other private payors to government payors or an increase in the number of uninsured patients may result in a reduction in the rates of reimbursement or an increase in uncollectible receivables or uncompensated care, with a corresponding decrease in net revenue. Policies now being offered under various insurance plans are expected to reduce demand for MRI scans as they become less affordable. Changes in the eligibility requirements for governmental programs such as the Medicaid program and state decisions on whether to participate in the expansion of such programs also could increase the number of patients who participate in such programs and the number of uninsured patients. Even for those patients who remain in private insurance plans, changes to those plans could increase patient financial responsibility, resulting in a greater risk of uncollectible receivables. These factors and events could have a material adverse effect on our business, financial condition, and results of operations.
| Page 39 |
FONAR CORPORATION AND SUBSIDIARIES
8. Federal and state privacy and information security laws. We must comply with numerous federal and state laws and regulations governing the collection, dissemination, access, use, security and privacy of PHI, including HIPAA and its implementing privacy and security regulations, as amended by the federal HITECH Act. If we fail to comply with applicable privacy and security laws, regulations and standards, properly maintain the integrity of our data, or protect our proprietary rights to our systems, our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.
9. Current and future changes in Florida Insurance Law. On March 24, 2023, Florida enacted House Bill 837. Dubbed the Tort Reform Act, the bill made sweeping changes to Florida’s negligence laws that negatively impact our Florida diagnostic imaging facilities (both those we own and those we manage) with more unpaid bills, higher administrative costs, and lower reimbursement rates. The full extent of those reductions are unclear at this time. Florida legislators continue to propose significant changes to the current structure of Florida’s insurance industry, which may impact our future operations in Florida.
10. Demand for MRI Scanners. The reduced reimbursement rates have a negative effect on our sales of MRI scanners. With lower revenue projections, prospective customers would demand lower prices for scanners. Although the reduced reimbursements may not affect foreign demand, a lower number of sales in the aggregate could reduce economies of scale and consequently, profit margins.
11. Manufacturing Competition. Many if not most of our competing scanner manufacturers have significantly greater financial resources, production capacity, and other resources than we do. Such competitors would include General Electric, Siemens, Hitachi and Phillips. Although FONAR is the only company which can manufacture and sell the unique Stand-Up® (Upright®) MRI scanner, potential customers must be convinced that the purchase of a FONAR scanner is their best choice. We believe that with time, that objective will be reached, particularly with customers scanning patients having neck, back, knee and various orthopedic issues who would benefit from being scanned in weight-bearing positions.
12. Other changes in Domestic and Worldwide Economic Conditions. We are subject to risk arising from adverse changes in general domestic and global economic and other conditions, including recessions or economic slowdowns, disruptions of credit markets and military conflicts. Turbulence and uncertainty in the United States and international markets and economies may adversely affect our workforce, liquidity, financial condition, revenues, profitability and business operations generally.
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds: None
In September 2022, our Board of Directors authorized a program to repurchase up to $9 million of our common stock. Under this program, we may purchase stock in the open market or through privately negotiated transactions in accordance with applicable securities laws, including pursuant to pre-arranged stock trading plans. The timing and actual amount of the stock repurchases will depend on several factors including price, capital availability, regulatory requirements, and other market conditions. We are not obligated to repurchase a specific number of shares under this program and it may be modified, suspended or discontinued at any time.
| Page 40 |
FONAR CORPORATION AND SUBSIDIARIES
The following table summarizes the number of shares repurchased during the three months ended December 31, 2024:
| Fiscal Month | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Programs | Maximum Dollar Value that May Still Be Purchased Under the Program (In Thousands) | ||||||||||||||
| October 1, 2024 – October 31, 2024 | 32,217 | $ | 15.62 | 32,217 | 3,815 | |||||||||||||
| November 1, 2024 – November 30, 2024 | 27,498 | $ | 15.39 | 27,498 | 3,392 | |||||||||||||
| December 1, 2024 – December 31, 2024 | 0 | $ | 0.00 | 0 | 3,392 | |||||||||||||
| Total | 59,715 | $ | 15.52 | 59,715 | ||||||||||||||
Item 3 - Defaults Upon Senior Securities: None
Item 4 - Mine Safety Disclosure: Not Applicable
Item 5 - Other Information
Rule 10b5-1 Trading Plan
During
the fiscal quarter ended December 31, 2024, none of our directors or executive officers
Item 6 - Exhibits and Reports on Form 8-K:
| Page 41 |
FONAR CORPORATION AND SUBSIDIARIES
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| FONAR CORPORATION | |
| (Registrant) | |
| By: /s/ Timothy Damadian | |
| Timothy Damadian | |
| Chairman of the Board of Directors, President, | |
| Principal Executive Officer and Treasurer | |
| /s/ Luciano Bonanni | |
| Luciano Bonanni | |
| Executive Vice President, Chief Operating Officer, | |
| Acting Principal Financial Officer | |
| Dated: February 19, 2025 |
Page 42